The effect of metformin or dipeptidyl peptidase 4 inhibitors on clinical outcomes in metastatic non‐small cell lung cancer treated with immune checkpoint inhibitors

BACKGROUND: Preclinical data have shown the immunomodulatory effects of metformin and dipeptidyl peptidase 4 (DPP4) inhibitors in patients with diabetes. However, its clinical impact remains unclear in lung cancer. METHODS: Between 2017 and 2021, 466 patients received ICI monotherapy. Patients were...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Jieun, Kim, Se Hyun, Jung, Eun Hee, Kim, Sang‐A, Suh, Koung Jin, Lee, Ji Yun, Kim, Ji‐Won, Kim, Jin Won, Lee, Jeong‐Ok, Kim, Yu Jung, Lee, Keun‐Wook, Kim, Jee Hyun, Bang, Soo‐Mee, Lee, Jong Seok
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807448/
https://www.ncbi.nlm.nih.gov/pubmed/36351567
http://dx.doi.org/10.1111/1759-7714.14711

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807448/
https://www.ncbi.nlm.nih.gov/pubmed/36351567
http://dx.doi.org/10.1111/1759-7714.14711

Ejemplares similares